-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy

Reuters·12/08/2025 00:00:45

Please log in to view news